Ongar, United Kingdom (31 May 2011). Selcia Limited (“Selcia”), a leading contract research organisation, today announced the appointment of Simon Bury as Business Development Director of its Discovery division, to lead expansion plans in its drug discovery offering.

Commenting on the appointment, Simon Saxby, CEO of Selcia, said: “We are delighted to welcome Simon Bury to Selcia Discovery’s rapidly expanding team. We look forward to Simon helping us develop our integrated drug Discovery division, and accelerate our growth into this strategic area, complementing our other world leading contract research services”.

Simon has over 30 years of commercial experience within the life sciences industry, and brings with him a strong mix of technical, strategic and business development expertise. Simon was most recently Chief Commercial Officer for Cyprotex Discovery Ltd, where he was responsible for the company’s global sales and marketing activities. Prior to Cyprotex, Simon held senior business development roles at Shanghai ChemPartner, Scottish Biomedical Ltd, Pharmacopeia Inc, Hewlett-Packard and Zymark Ltd.

On joining Selcia, Simon Bury commented, “Selcia Discovery has established a fabulous reputation for delivering high quality integrated drug discovery services to the global pharmaceutical and biotechnology industry. I am very much looking forward to using my experience to further advance this business”.

ENDS

Notes for editors:

About Simon Bury
Simon is an Applied Biochemistry graduate from John Moore’s University in Liverpool and has held directly related commercial roles in the life science industry for over 30 years. Simon was most recently Chief Commercial Officer at Cyprotex Discovery Ltd where he was responsible for the company’s global sales and marketing activities.

Prior to Cyprotex, Simon’s roles included Executive Director of Business Development at Shanghai ChemPartner; Business Development Director at Scottish Biomedical Ltd; Business Development Manager at Pharmacopeia Inc; and over 10 years at Hewlett-Packard where Simon was UK Pharmaceutical Accounts Manager. He has also held the position of UK Sales Manager for Zymark Ltd.

About Selcia
Selcia Limited is a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry. Selcia operate from 2,800sqm modern facilities with a GLP analytical laboratory, in Ongar, Essex, UK.

Selcia’s Discovery division provides integrated drug discovery services to the pharmaceutical and biotechnology industries; these services include medicinal, organic and analytical chemistry, molecular modelling, in vitro biological screening, fragment screening and in vitro ADME/PK evaluation as well as in vivo PK (with a strategic partner). Selcia’s scientists act as integrated project teams within the customer group striving to produce viable drug candidates against its partners’ biological targets. Selcia’s capillary electrophoresis screening platform offers unique opportunities for biological screening of many important target classes. Its proprietary fragment screening service, CEfrag™, is a powerful application of the technique at the outset of a drug discovery programme. CEFrag™ was nominated for ‘Killer Technology’ in the 2010 East of England Business Awards.

Selcia’s Radiolabelling division is a proven leader in delivering pure radiolabelled compounds for preclinical and clinical ADME studies.